Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials.

See related article by Ahn et al., p. 2039

©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.